|
Berger AM, Clark-Snow RA. Nausea and vomiting. In: DeVita VT,
Hellman S, Rosenberg SA, eds. Cancer:
Principles and Practice of Oncology. 7th ed. Philadelphia,
Pa: Lippincott Williams & Wilkins; 2005: 2515-2523.
Berger AM, Fall-Dickson JM. Oral complications. In: DeVita VT,
Hellman S, Rosenberg SA, eds. Cancer:
Principles and Practice of Oncology. 7th ed. Philadelphia,
Pa: Lippincott Williams & Wilkins; 2005: 2523-2535.
Gullatte MM, Gaddis J. Chemotherapy. In: Varrichio CG, ed. A Cancer Source Book for Nurses.
8th ed. Sudbury, Mass: Jones and Bartlett; 2004:103-130.
Hurria A, Somlo G, Ahles T. Renaming "chemobrain". Cancer Invest. 2007
Sep;25(6):373-7.
Itano JK, Taoka KN, eds. Core
Curriculum for Oncology Nursing. 4th ed. Philadelphia, Pa:
Elsevier Saunders; 2005.
Macklin DC. Developing a Patient-Centered Approach to Vascular
Access Device Selection. Medscape Nurses, 08/17/2005. Accessed at:
www.medscape.com/viewarticle/508093_1 on May 21, 2009.
NCCN Clinical Practice Guidelines in Oncology. Antiemesis,
V.3.2009. Accessed at:
www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf on May 20,
2009.
NCCN Clinical Practice Guidelines in Oncology. Cancer- and
Chemotherapy-Induced Anemia, V. 3.2009. Accessed at:
www.nccn.org/professionals/physician_gls/PDF/anemia.pdf on May 19,
2009.
National Cancer Institute FactSheet: Cancer Vaccines. Reviewed
3/17/2009. Accessed at:
www.cancer.gov/cancertopics/factsheet/cancervaccine on May 19, 2009.
Perry MC, Anderson CM, Donehower RC. Chemotherapy. In: Abeloff
MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, eds. Clinical Oncology.
3rd ed. Philadelphia, Pa: Elsevier Churchill Livingstone; 2004:
483-535.
Radiological Society of North America. Vascular Access
Procedures. Accessed at:
www.radiologyinfo.org/en/info.cfm?pg=vasc_access on May 21, 2009.
Sung L, Nathan PC, Alibhai SM, et al. Meta-analysis: effect of
prophylactic hematopoietic colony-stimulating factors on mortality and
outcomes of infection. Ann
Intern Med. 2007 Sep 18;147(6):400-11.
US FDA, CDER. Communication about an Ongoing Safety Review:
Erythropoiesis-Stimulating Agents (ESAs) Epoetin alfa (marketed as
Procrit, Epogen) Darbepoetin alfa (marketed as Aranesp). Accessed at:
http://www.fda.gov/cder/drug/early_comm/ESA.htm on February 26, 2008.
Weiss RB. Miscellaneous toxicities. In: DeVita VT, Hellman S,
Rosenberg SA, eds.
Cancer: Principles and Practice of Oncology. 7th ed.
Philadelphia, Pa: Lippincott Williams & Wilkins; 2005:
2602-2614.
Yarbro CH, Goodman M, Frogge MH, Groenwald SL. Cancer Nursing: Principles and
Practice. 5th ed. Sudbury, Mass: Jones and Bartlett; 2000.
Go back
to Chemotherapy
Principles
Last Medical Review: 06/17/2009
Last Revised: 06/17/2009
|
